Gender Differences and Features of the Clinical Course of Primary Headaches

Sponsor
Tashkent Medical Academy (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05760625
Collaborator
(none)
120
1
27.3
4.4

Study Details

Study Description

Brief Summary

The pathophysiological mechanisms that underlie primary headache disorders, such as migraine and cluster headache (CH), are complex and not yet fully clarified. While there is today little doubt that activation of the trigeminovascular system (TGVS) is responsible for the headache pain, the primary mechanisms, probably centrally mediated, leading to its activation and the generation of pain are still largely obscure. The trigeminal system is supposed to play a central role not only in migraine but also in cluster headache pathology. In vitro studies have demonstrated the expression of BDNF in trigeminal ganglion neurons. BDNF release is induced by trigeminal stimulation and nociceptive inputs. BDNF is a member of the neurotrophin family and has been recognized as an important modulator of nociceptive pathways. Interestingly, BDNF is co-expressed with CGRP in trigeminal ganglion neurons. CGRP is one of the key molecules in migraine and cluster headache pathogenesis. BDNF is an important marker of neuronal plasticity. It has also been associated with pain processing. Increased BDNF levels are observed in chronic pain syndromes. In order to understand the role of BDNF associated with other factors such as gender on headache attacks we aimed to determine whether migraine and cluster headache is correlated with brain derived neurotrophic factor (BDNF) level, gender and age.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: analysis BDNF

Detailed Description

Patients will recruite among those attending the Clinic of Tashkent Medical Academy,

Uzbekistan. Three groups of headache patients will be enrolled in this prospective study:

patients with episodic migraine with and without aura, episodic cluster headache, and frequent episodic tension-type headache according to the current criteria of the

International Headache Society. In migraineurs, venous blood samples will be collected twice:

outside and during migraine attacks prior to pain medication. In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF will performed using enzyme-linked immunosorbent assay technique. In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take.Patients with a history of cardiovascular disease, major depression, hypertension, drug or alcohol abuse, or other apparent diseases will be excluded from the study. The research will comprise 120 patients (males and females) suffering from primary headache. At the moment we started collecting patients.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
120 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Gender Differences and Features of the Clinical Course of Primary Headaches
Actual Study Start Date :
Dec 10, 2020
Actual Primary Completion Date :
Oct 20, 2022
Anticipated Study Completion Date :
Mar 21, 2023

Arms and Interventions

Arm Intervention/Treatment
Migraine

In migraineurs, venous blood samples will be collected twice: outside and during migraine attacks prior to pain medication. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.

Diagnostic Test: analysis BDNF
We analysed consentration of BDNF in venous blood of patient with primary headache

Tension type of headache

In patients with tension-type headache (outside attack) and healthy controls, one single blood sample will take. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.

Diagnostic Test: analysis BDNF
We analysed consentration of BDNF in venous blood of patient with primary headache

Cluster headache

In cluster headache patients serum samples will be collected in and outside cluster bout. Analysis of BDNF performed using enzyme-linked immunosorbent assay technique.

Diagnostic Test: analysis BDNF
We analysed consentration of BDNF in venous blood of patient with primary headache

Outcome Measures

Primary Outcome Measures

  1. Gender differences and features of the clinical course of primary headaches [2 years]

    Increasing of BDNF during headache attacks in women were more than men

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Migraine patients were included if they suffered from at least one, but no more than eight migraine attacks per month, and had not taken any pain medication including non-steroidal anti inflammatory drugs (NSAIDs), triptans or opioids 48 h prior to blood sample collection and if phone contact was possible 3 days after blood sampling.
Exclusion Criteria:
  • Patients were not included if they had a history of cardio or cerebrovascular disease, diabetes, cancer, severe renal or hepatic disease. Patients with more than one diagnosis of a primary headache, i.e. coexistent migraine and tension-type headache, were excluded from study participation. Pregnancy and breastfeeding were additional exclusion criteria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tashkent Medical Academy Tashkent Olmazor District Uzbekistan 100109

Sponsors and Collaborators

  • Tashkent Medical Academy

Investigators

  • Study Chair: Bahtigul Holmuratova, PhD student, Tashkent Medical Academy

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bahtigul Holmuratova, Dr. Bahtigul, Tashkent Medical Academy
ClinicalTrials.gov Identifier:
NCT05760625
Other Study ID Numbers:
  • 616.857-036:616.831:615.21
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 8, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Bahtigul Holmuratova, Dr. Bahtigul, Tashkent Medical Academy
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 8, 2023